Checkpoint inhibitors in the treatment of brain metastases of non-small-cell lung cancer and melanoma.
Future Oncol
; 13(12): 1097-1103, 2017 May.
Article
em En
| MEDLINE
| ID: mdl-28326837
ABSTRACT
Brain metastases (BMs) are representing a new challenge for the oncologist; their incidence is increasing due to the better overall survival and systemic disease control in many malignancies, consequent to new potent cytotoxic and targeted therapies. In the era of immunotherapies, checkpoint inhibitors are representing a new therapeutic option in different solid tumors and settings; preliminary results showed potential activity of these agents in patients with BM, when administered as single agent or in combination with radiation therapy. After presenting the arguments in favor of this new strategy, we reported the preliminary results of the trials evaluating these agents in BM, we described the ongoing trials and we discussed the potential role of these agents in the BM treatment.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Encefálicas
/
Carcinoma Pulmonar de Células não Pequenas
/
Terapia de Alvo Molecular
/
Neoplasias Pulmonares
/
Melanoma
Limite:
Humans
Idioma:
En
Revista:
Future Oncol
Ano de publicação:
2017
Tipo de documento:
Article
País de afiliação:
Líbano